

Journal of the American Academy of Child and Adolescent Psychiatry

Neuroendocrine stress response in female and male adolescents with Conduct Disorder and associated early adversity

--Manuscript Draft--

Manuscript Number:	
Full Title:	Neuroendocrine stress response in female and male adolescents with Conduct Disorder and associated early adversity
Short Title:	Stress response in Conduct Disorder
Article Type:	Research Article
Keywords:	Conduct Disorder, stress response, Cortisol, Testosterone, Oxytocin, early adversity
Corresponding Author:	Anka Bernhard, Ph.D. University Hospital Frankfurt am Main, Goethe University Frankfurt am Main Frankfurt am Main, Hessen GERMANY
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	University Hospital Frankfurt am Main, Goethe University Frankfurt am Main
Corresponding Author's Secondary Institution:	
First Author:	Anka Bernhard, Dr.
First Author Secondary Information:	
Order of Authors:	Anka Bernhard, Dr. Katharina Ackermann, Dr. Anne Martinelli, Dr. Leonora Vllasaliu, Dr. Karen Gonzalez-Madruga, Dr. Molly Batchelor, BSc Nora Raschle, Prof. Dr. Helena Oldenhof, MSc Lucres Jansen, Dr. Gregor Kohls, Dr. Kerstin Konrad, Prof. Dr. Arne Popma, Prof. Dr. Christina Stadler, Prof. Dr. Graeme Fairchild, Dr. Christine M. Freitag, Prof. Dr.
Order of Authors Secondary Information:	
Manuscript Region of Origin:	GERMANY
Abstract:	Objective: Conduct disorder (CD) involves aggressive and antisocial behavior and is associated with blunted cortisol responses to stress in male adolescents. However, far less is known about cortisol stress responsivity in females with CD or other neuroendocrine systems in both sexes. Although CD is linked to early adversity, the possibility that neuroendocrine system alterations mediate the relationship between early adversity and CD has not been systematically investigated.

Method: Within the FemNAT-CD multi-site study, salivary cortisol, testosterone, and oxytocin levels as well as psychological stress in response to a standardized psychosocial stress test (the Trier Social Stress Test) were assessed in 130 pubertal adolescents with CD (63% female, 9-18 years) and 160 sex-, age-, and puberty-matched healthy controls. Common pre- and postnatal environmental risk factors were also assessed.

Results: Females and males with CD both showed blunted cortisol, testosterone, and oxytocin responses to stress compared to healthy controls. In contrast, the CD group reported higher levels of psychological stress. Psychoneuroendocrine stress responses partly mediated the relationship between environmental risk factors and CD.

Conclusion: Findings provide evidence for a widespread attenuated stress responsivity of not only the stress hormone, but also sex hormone and neuropeptide systems in CD. Our results are the first to demonstrate similarly blunted neuroendocrine stress response in both females and males with CD. Results of mediation analyses suggest a mechanism through which early adversity increases risk for CD. Considering neurobiological characteristics and associated environmental risks in personalizing an individual's treatment may help to improve future interventions for CD.



Dept. of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy • Goethe University Hospital
Deutschordenstraße 50 • 60528 Frankfurt/Main
Dr. Anka Bernhard (PhD)
Phone: +49(0)69-6301-7178 • Email: anka.bernhard@kgu.de

To the Editor-in-chief
Douglas K. Novins, MD
*Journal of the American Academy of
Child & Adolescent Psychiatry*

Frankfurt/M., 15.01.2021

Manuscript submission to the *Journal of the American Academy of Child & Adolescent Psychiatry*

Dear Dr. Novins,

please find attached our manuscript "*Neuroendocrine stress response in female and male adolescents with Conduct Disorder and associated early adversity*" which we are submitting for publication in the *Journal of the American Academy of Child & Adolescent Psychiatry*.

Conduct Disorder (CD) is one of the most impairing, but also one of the most understudied mental disorders of childhood and adolescence, especially in females. CD is associated with blunted cortisol responses to stress in male adolescents. However, far less is known about stress responsivity in females with CD, or alterations in additional neuroendocrine systems in both sexes.

To our knowledge, our study is the largest in the literature to date (N=290) on neuroendocrine stress responsivity in CD compared to healthy controls, and the first to simultaneously investigate biomarkers of the HPA-axis (cortisol), HPG-axis (testosterone) and neuropeptide (oxytocin) systems next to psychological stress in response to a standardized psychosocial stress test (the Trier Social Stress Test) in both females and males with CD. Our study is the

first to demonstrate that females with CD show similarly attenuated HPA-axis responses to stress as males with CD, and that these alterations extend to the HPG-axis and neuropeptide systems in both sexes compared to healthy adolescents. Interestingly, an increased psychological stress response was observed in individuals with CD, suggesting poorer coordination of neuroendocrine and psychological stress responses in CD. Furthermore, this study explored whether alterations in neuroendocrine stress responses mediate the effects of early adversity on CD. Altered neuroendocrine responses to stress partly mediated the relationship between pre- and postnatal risk factors and CD suggesting a mechanism by which early adversity increases risk for CD.

Overall, our findings substantially extend our understanding of the neurobiological basis of CD and enhance knowledge about risk factors and mechanisms involved in CD. We believe our work will be of interest to a broad audience, such as the readership of the *Journal of the American Academy of Child & Adolescent Psychiatry*.

This manuscript and its data are original, have been contributed by the stated authors, have not been published previously and are not under consideration for publication elsewhere. All authors have approved the final submission.

Thank you very much for your consideration. We look forward to hearing from you.

Yours sincerely,

Dr. Anka Bernhard



Signed on behalf of all co-authors

Neuroendocrine stress response in female and male adolescents with Conduct Disorder and associated early adversity

Running head: Stress response in Conduct Disorder

Anka Bernhard, ^{PhD}, Katharina Ackermann, ^{PhD}, Anne Martinelli, ^{PhD}, Leonora Vllasaliu, ^{PhD},
Karen Gonzalez-Madruga, ^{PhD}, Molly Batchelor, ^{BSc}, Nora Maria Raschle, ^{PhD}, Helena
Oldenhof, ^{MSc}, Lucres Jansen, ^{PhD}, Gregor Kohls, ^{PhD}, Kerstin Konrad, ^{PhD}, Arne Popma, ^{PhD},
Christina Stadler, ^{PhD}, Graeme Fairchild, ^{PhD}, & Christine M. Freitag, ^{MD, PhD (Habilitation)}

Authors' affiliations: Drs. Bernhard, Ackermann, Martinelli and Vllasaliu, and Professor Dr. Freitag are with the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany. Dr. Gonzalez-Madruga and Mss. Batchelor are with the Department of Psychology, University of Southampton, Southampton, UK. Professor Dr. Raschle is with the Jacobs Center for Productive Youth Development at the University of Zurich, Zurich Switzerland, and with the Psychiatric University Clinic and University of Basel, Basel, Switzerland. Professor Dr. Popma, Dr. Jansen and Mss. Oldenhof are with the VU University Medical Center, Amsterdam, The Netherlands. Dr. Kohls and Professor Dr. Konrad are with the Child Neuropsychology Section, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital RWTH Aachen, Aachen, Germany. Professor Dr. Konrad is also with the JARA-Brain Institute II, Molecular Neuroscience and Neuroimaging, RWTH Aachen & Research Centre Juelich, Juelich, Germany. Professor Dr.

Stadler is with the Psychiatric University Clinic and University of Basel, Basel, Switzerland.
Dr. Fairchild is with the University of Bath, Bath, UK.

Corresponding author: Anka Bernhard, Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt, Goethe University Frankfurt am Main, Deutschordenstraße 50, 60528 Frankfurt am Main, Germany. Phone number: +496963017178. E-mail address: anka.bernhard@kgu.de.

Acknowledgements: This study was funded by the European Commission's Seventh Framework Program (FP7 grant no. 602407; FemNAT-CD, coordinator Professor Dr. Christine M. Freitag). The authors sincerely thank the adolescents and their parents/caregivers for participating, Mr. Ronald Limprecht (IMBI Heidelberg) for managing the central database, Dr. Juliane Hellhammer, Ms. Anne Dubberke (both Daacro's Saliva Lab, Trier, Germany) and Professor Dr. Rainer Landgraf (RIAGnosis, Sinzing, Germany) for their laboratory assistance, and Professor Dr. Clemens Kirschbaum (Department of Psychology, TU Dresden, Germany) and Dr. Marietta Kirchner (IMBI Heidelberg) for their scientific support.

Presentation information: Preliminary data from this study was presented at the Society of Biological Psychiatry's 72th Meeting, San Diego, USA, May 18-20, 2017, the 13th World Congress of Biological Psychiatry, Copenhagen, Denmark, June 18-22, 2017, the European Association for Forensic Child & Adolescent Psychiatry, Psychology & other involved professions' 6th Meeting, Venice, Italy, June 20-22, 2018, and the International Society for Research on Aggression's 23th Meeting, Paris, France, July 10-14, 2018.

Disclosure: Professor Dr. Konrad has received speaker fees from Shire Pharmaceuticals and Medice and receives royalties for books. Professor Dr. Stadler receives royalties for a book on aggression. Professor Dr. Freitag receives royalties for books on Autism Spectrum Disorder, ADHD, and depressive disorder. Drs. Bernhard, Ackermann, Martinelli, Vllasaliu, Gonzalez-Madruga, Raschle, Jansen, Kohls, Popma and Fairchild, and Mss. Batchelor and Oldenhof have reported no biomedical financial interests or potential conflict of interest.

**Neuroendocrine stress response in female and male adolescents with Conduct Disorder
and associated early adversity**

Running head: Stress response in Conduct Disorder

Word count (without abstracts, tables, figures, or references): 4499

Keywords: Conduct Disorder, stress response, Cortisol, Testosterone, Oxytocin, early
adversity

Abstract

Objective: Conduct disorder (CD) involves aggressive and antisocial behavior and is associated with blunted cortisol responses to stress in male adolescents. However, far less is known about cortisol stress responsivity in females with CD or other neuroendocrine systems in both sexes. Although CD is linked to early adversity, the possibility that neuroendocrine system alterations mediate the relationship between early adversity and CD has not been systematically investigated.

Method: Within the FemNAT-CD multi-site study, salivary cortisol, testosterone, and oxytocin levels as well as psychological stress in response to a standardized psychosocial stress test (the Trier Social Stress Test) were assessed in 130 pubertal adolescents with CD (63% female, 9-18 years) and 160 sex-, age-, and puberty-matched healthy controls. Common pre- and postnatal environmental risk factors were also assessed.

Results: Females and males with CD both showed blunted cortisol, testosterone, and oxytocin responses to stress compared to healthy controls. In contrast, the CD group reported higher levels of psychological stress. Psychoneuroendocrine stress responses partly mediated the relationship between environmental risk factors and CD.

Conclusion: Findings provide evidence for a widespread attenuated stress responsivity of not only the stress hormone, but also sex hormone and neuropeptide systems in CD. Our results are the first to demonstrate similarly blunted neuroendocrine stress response in both females and males with CD. Results of mediation analyses suggest a mechanism through which early adversity increases risk for CD. Considering neurobiological characteristics and associated environmental risks in personalizing an individual's treatment may help to improve future interventions for CD.

Introduction

Conduct Disorder (CD) is characterized by aggressive, antisocial and rule-breaking behavior, and is one of the most impairing, but also one of the least studied mental disorders in childhood and adolescence, particularly in females ¹. While prevalence rates have increased in recent decades, studies on females with CD remain scarce ². A growing body of evidence indicates that CD is associated with neurobiological alterations, such as changes in brain, autonomic nervous system, or neuroendocrine functioning.

One of the major neurobiological characteristics associated with CD is altered hypothalamic-pituitary-adrenal (HPA)-axis activity ³. The HPA-axis is essential for responding to and regulating the impact of stress. During stress, the hypothalamus releases corticotropin-releasing hormone, triggering adrenocorticotropin release from the pituitary. Adrenocorticotropin stimulates the adrenal gland to release cortisol into the bloodstream ⁴. Salivary cortisol serves as a widely used peripheral marker of HPA-axis functioning ⁵. Despite similar subjective emotional responses, lower salivary cortisol stress responses to public-speaking or anger-provocation tasks have been consistently reported in males with CD compared to healthy individuals (see ⁶ for review). Importantly, it is unknown whether females with CD show similarly attenuated HPA-axis responsivity to stress, although lower morning cortisol levels have been reported in girls with CD compared to healthy controls ⁷.

Notably, previous studies on neuroendocrine stress responsivity in CD focused on the HPA-axis, mainly by assessing cortisol. This is surprising given the complex interplay between the major neuroendocrine systems, which are assumed to work in a coordinated manner to enable successful stress regulation in both females and males ⁸⁻¹⁰. For example, the hypothalamic-pituitary-gonadal (HPG)-axis interacts with the HPA-axis ⁴. A corresponding stress responsivity of the HPA- and HPG-axes is assumed given the positive correlation of

cortisol and the sex hormone testosterone in response to stress in healthy children and adults ⁸. While positive associations between basal testosterone, aggressive behavior and CD were reported ¹¹, sex hormones have not been assessed under stressful conditions in CD. Additionally, neuropeptides (e.g., oxytocin) influence HPA-axis responsivity. Oxytocin inhibits HPA-axis activity, evoking stress-protective and anxiolytic effects ¹⁰. Most stressors that stimulate HPA-axis activity also activate the oxytocin system ¹². Accordingly, peripheral salivary cortisol and oxytocin are co-activated under stress in healthy adolescents and adults, with oxytocin release preceding cortisol secretion ^{13,14}. While basal oxytocin system alterations have been reported ¹⁵, the oxytocin response to stress has not been investigated in adolescents with CD. Given the simultaneous activation of HPA-axis, HPG-axis, and neuropeptide systems in response to stress, it is important to apply a multi-system approach to understand the overarching neurobiology of stress regulation in CD.

In addition, given that CD is strongly associated with early adversity ¹⁶, findings of blunted neuroendocrine stress responsivity may be influenced by exposure to prenatal (e.g., maternal smoking or violence exposure) or postnatal risk factors (e.g., exposure to trauma or familial conflicts). Such early adversity has been associated with altered HPA-axis, HPG-axis and neuropeptide system functioning in adolescents and adults ¹⁷⁻¹⁹. Attenuated neuroendocrine stress responsivity may represent an adaptation to early-life adversity which would otherwise overload the neuroendocrine systems ²⁰. A recent review highlighted the importance of considering the impact of adversities such as early-life trauma in neuroendocrine research on CD ²¹. While no previous study investigated whether neuroendocrine stress responses mediate the relation between early adversity and CD, such work is strongly warranted to understand the neurobiological mechanisms that may underpin the association between early adversity and CD.

Overall, previous neuroendocrine research in CD focused on HPA-axis functioning in response to stress and neglected other related neuroendocrine systems as well as the possibility that the effects of early environmental risk for CD are mediated by neuroendocrine alterations. Critically, all previous research on neuroendocrine responsivity was limited to males with CD, thus almost nothing is known about stress responsivity in females with CD. To address these research gaps, we investigated HPA-axis (cortisol), HPG-axis (testosterone) and neuropeptide (oxytocin) responses to a standardized psychosocial stress test in males and females with CD compared to sex-matched healthy controls (HCs). Given previous evidence of cortisol hypo-reactivity in females and males with CD ^{6,7}, and coordinated HPA-axis, HPG-axis and neuropeptide responsivity to stress ^{8,10}, we hypothesized an overall attenuated neuroendocrine stress responsivity in females and males with CD compared to HCs. Additionally, we explored whether neuroendocrine stress responses mediated the relationship between common pre- and postnatal risk factors and CD.

Method

Participants

This study included 130 pubertal adolescents (9-18 years) with CD (82 females) and 160 healthy adolescents (104 females) from the European “Neurobiology and Treatment of Female Conduct Disorder” (FemNAT-CD) project ². Data were collected between 2014 and 2017 across five European sites (Germany, Switzerland, the Netherlands, and the UK; see Table S1). Most participants were born in the country of assessment (Mean [SD], %: adolescents 95.04 [2.96], parents 75.11 [8.94]). Local ethical committees at each site approved the study. Participants were recruited from clinics, youth offending services, schools, and the community (e.g., via newspaper adverts or social media). Written informed consent was obtained from all participants and/or their legal guardians after a detailed study description. Exclusion criteria included IQ<70, pre-pubertal status, pregnancy, last menstruation >6 months ago, history of neurological disorder, traumatic brain injury, schizophrenia, autism spectrum disorder, or current mania or bipolar disorder. Adolescents with CD fulfilled DSM-IV-TR criteria for current CD ²². HCs had neither current DSM-IV-TR disorders nor a history of disruptive behavior- or attention-deficit/hyperactivity disorder (ADHD).

Procedures

Current and lifetime psychiatric disorders were assessed with the Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime version (K-SADS-PL, ²³), a semi-structured diagnostic interview conducted separately with adolescents and parents/caregivers by trained staff. Inter-rater reliability (Cohen’s κ =.91) and agreement (95%) for CD were high (N=75). For comorbid psychiatric disorders (e.g., ADHD, oppositional defiant disorder, major depressive disorder [MDD], Posttraumatic Stress Disorder [PTSD]) inter-rater reliabilities (Cohen’s κ =.50-.95) and agreements (92-95%) were

1 moderate to high. IQ was estimated from the matrix reasoning and vocabulary subtests of the
2 Wechsler Intelligence Scale-IV (11-16 years ²⁴; >16 years ²⁵). The UK site used the Wechsler
3 Abbreviated Scale of Intelligence ²⁶. Parental educational status was defined as the mean of
4 the highest maternal and paternal self-reported school or occupational degree following
5 International Standard Classification of Education (ISCED) criteria ²⁷. ISCED criteria for
6 parental educational status are based on six categorical levels: 0=pre-primary level of
7 education, 1=primary level of education, 2=lower secondary level of education, 3=upper
8 secondary level of education, 4=post-secondary level of education, 5=first stage of tertiary
9 education, 6=second stage of tertiary education. Pubertal status was assessed using the
10 Pubertal Development Scale ²⁸, a self-report measure of pubertal growth (e.g. changes in body
11 hair, voice or breast development) with four response options (not yet, barely or definitely
12 started, seems complete) resulting in a five-level categorical scale (0=pre-pubertal, all items
13 not yet started; 1=early-pubertal, at least one item barely started; 2=mid-pubertal, at least one
14 item definitely started; 3=late-pubertal, all items definitely started, 4=post-pubertal, all items
15 seems complete). The internal consistency was $\alpha=0.77$ ²⁸. Parents/caregivers reported on four
16 widely replicated pre- and postnatal risk factors: prenatal smoking and violence exposure
17 (yes/no), adverse family situation (summary score of familial disharmony and isolation due to
18 correlation $r>0.3$, three categories: 0=zero yes responses, 1=yes to either disharmony or
19 isolation, 2=yes to both items), and the number of DSM-IV-TR traumatic events experienced
20 (based on 11 potentially traumatic experiences from the K-SADS-PL PTSD section, e.g., life-
21 threatening accidents, disasters, or physical/sexual abuse, summary score self- and parent-
22 rating).

23 ***Psychoneuroendocrine assessment***

24 Stress responsivity (see Figure 1) was assessed with the Trier Social Stress Test (TSST) ²⁹, a
25 widely-used, standardized method for inducing psychosocial stress in laboratory settings ³⁰.

After a 60- minute relaxation period in a comfortable room (Room A) to minimize possible effects of previous food/drink intake, exercise, or stressful events, the baseline assessments were taken. Next, participants entered a sparsely-equipped experimental room (Room B) and were introduced to the task. After a short preparation period, they had to give a public speech (about their favorite movie including the storyline and their opinions of the characters and plot), followed by an age-adapted mental arithmetic task (serial subtraction of a fixed number from a given starting number, e.g., 13 from 1023, starting again from the beginning if they gave the wrong answer). Both tasks were performed in front of two unfamiliar panel members and a video camera. Post-stress assessments were completed in Room A. Participants were given positive feedback about their performance, informed that no recordings were made, and fully debriefed. Alcohol/substance use was not permitted on the assessment day nor drinking, eating, or smoking during the whole experiment. To confirm stress induction, participants rated their feelings of stress (“Do you feel stressed?”) eight times from baseline to +55 minutes after stress termination using a Visual Analog Scale (range 0-10) ³¹. Saliva samples were collected using Salivettes (Sarstedt, Germany) at baseline and +1, +10, +25, +40 and +55 minutes after stress termination. Samples were stored at -20°C until analysis.

[Figure 1]

Levels of salivary cortisol (nmol/l) at baseline, +10, +25, +40 and +55 minutes, and testosterone (pg/ml) at baseline, +10 and +55 minutes were analyzed by Daacro (Trier, Germany) employing an enzyme immunoassay kit (Salimetrics, LLC, USA) formatted to minimize cross-reactivity for related steroids. The sensitivity limit was 0.19-82.77 nmol/l for cortisol and 1-600 pg/ml for testosterone. The corresponding inter- and intra-assay coefficients of variation were in the commonly accepted range (<15% and 10%, respectively ³²). After the cortisol and testosterone analyses, the baseline, +1 and +10 minutes salivettes were transferred to RIAgnosis (Sinzing, Germany) for quantification of salivary oxytocin

(pg/ml) by radioimmunoassay as described previously¹³. For each sample, 300 µl of saliva was evaporated (Concentrator, Eppendorf, Germany) and 50µl of assay buffer was added followed by 50µl rabbit antibody against oxytocin. The detection limit was in the 0.5 pg/sample range. Intra- and inter-assay coefficients of variation were <10%. Oxytocin was measured in a sub-sample of 170 participants (for site distribution see Table S1), including 80 adolescents with CD (45 females) and 90 HCs (49 females), as collection of samples at the +1 minutes timepoint (optimal for oxytocin) commenced later than the other timepoints. Different timepoints for cortisol, testosterone and oxytocin analyses were used based on reported distinct reactivity patterns^{14,30}.

Statistical Analyses

Statistical analyses were performed using SPSS v24 (IBM Corp., Armonk, NY). Significance levels of all tests were set at $p \leq 0.05$ (two-tailed). The groups' demographic and clinical characteristics were compared using univariate analyses of variance or Chi-Squared-tests. Neuroendocrine analyses controlled for age, current smoking, body mass index (BMI), TSST start time, medication (incl. contraceptive) use, and site; psychological stress analyses for age and site.

Neuroendocrine data was complete for all assessed timepoints of all participants. First, psychoneuroendocrine stress responses were analyzed using repeated measures analyses of co-variance on the dependent variables cortisol, testosterone, oxytocin, and psychological stress with group (CD vs. HCs) and sex (female vs. male) as between-subjects factors, and time as a within-subject factor. Significant main or interaction effects were followed by post-hoc Bonferroni-corrected pairwise comparisons. Neuroendocrine measures were log-transformed to normalize their distribution. For easier interpretation, Figure 1 shows the untransformed data. Dimensional covariates (age, BMI, TSST start time) were mean-centered³³. Greenhouse-Geisser corrections were applied as required, but for clarity uncorrected

degrees of freedom are reported. Effect sizes are described using partial eta squared η^2_p with 0.01 representing a small, 0.06 a medium and 0.14 a large effect ³⁴. Our sample size enabled us to detect even small, including group-by-sex interaction effects, with a power of 80% and a two-sided significance level of 5% (G*Power 3.1.9.2). To exclude confounding, the influence of IQ, pubertal status, and psychiatric comorbidities (ADHD, MDD, PTSD, substance use disorder (SUD), anxiety disorders (ANX)) was controlled for in additional separate analyses. Correlations between CD age-of-onset and CD severity with area under the curve measures (see below) for cortisol, testosterone, oxytocin, and psychological stress were calculated using Spearman-correlations.

Second, to explore mediating effects of psychoneuroendocrine responses (M) on associations between pre- or post-natal risk factors (X) and CD status (Y), mediation analyses were performed using the PROCESS macro (<http://www.processmacro.org/>). Therefore, aggregated psychoneuroendocrine stress response measures were computed ¹⁴. As a routinely used measure for overall stress response, the area under the curve with respect to increase (AUC_I), referring to the baseline level, was calculated. To explore stress reactivity and stress regulation separately, stress-increase (difference baseline-peak) and post-stress recovery (difference peak-lowest level after stress termination) were calculated. For each risk factor and possible mediator (aggregated psychoneuroendocrine stress measures), a mediation analysis was run yielding direct, indirect, and total effects. These were: a) a linear regression model of the mediator as a function of the risk factor (direct effect X→M), b) a logistic regression model of the case-control-status as a function of the mediator (direct effect M→Y) as well as of the risk factor (direct effect X→Y), and c) a logistic regression model of the case-control-status as a function of the risk factor (indirect effect X→M→Y). The standardized estimates of the effects are reported together with the proportion of the total effect mediated by each measure. Applying bootstrapping with 1000 resamples, percentile

bootstrap confidence intervals for the indirect effects were computed. The null hypothesis of no mediation effect was rejected if the 95% confidence interval did not include 0³⁵. As the mediation analyses tested for associations between risk factors and psychoneuroendocrine stress measures in an exploratory fashion, results are presented descriptively without correction for multiple comparisons.

Results

Sample characteristics

Groups did not significantly differ in sex, age, pubertal status, TSST start time, nor in baseline cortisol, testosterone, and oxytocin levels or psychological stress ratings. Participants with CD had higher BMIs and rates of current smoking and medication use, but lower IQ and parental educational status than HCs. Participants with CD had higher rates of risk factors and psychiatric comorbidities than HCs (see Table 1). Most female participants had started menstruating (CD 92%, HCs 79%) with comparable days since the last menstruation (Mean [SD]: CD 21.16 [18.22], HCs 20.09 [14.15], $p=.71$). Results for the oxytocin subsample were similar (see Table S2).

[Table 1]

Repeated-measures analyses of psychoneuroendocrine stress responses

The TSST induced significant neuroendocrine stress responses in HC, but not CD participants, with the two groups differing for all neuroendocrine measures (see Figure 2, Table 2). As evidenced by significant group-by-time interaction effects followed up using post-hoc Bonferroni-corrected pairwise comparisons, neither cortisol, nor testosterone or oxytocin increased in response to stress in participants with CD, whereas strong increases in all three neuroendocrine measures were observed in HCs. Regarding sex, similar attenuations of cortisol, testosterone, and oxytocin responses were found in females and males with CD (no group-by-sex-by-time interaction effects, except for testosterone indicating a sex effect only in HCs) while testosterone was generally higher in males and oxytocin higher in females.

In contrast, the TSST induced a significant psychological stress response in CD and HC participants (main effect of time). Interestingly, adolescents with CD reported higher overall psychological responses than HCs (significant group effect). Bonferroni-corrected

1 post-hoc comparisons indicated slower psychological post-stress recovery in CD participants
2 than HCs, with higher levels for the post-stress assessments (see Figure 2). No group-by-time
3
4 interaction effect was found, indicating similar psychological responses to the TSST in both
5
6 groups. In addition, no interactions with sex were observed, suggesting increased
7
8 psychological stress responses in both females and males with CD relative to HCs.
9
10

11
12
13 [Table 2, Figure 2]
14
15

16 ***Additional analyses for potential confounders on psychoneuroendocrine stress responses***

17 Repeating the analyses with IQ included as a covariate did not affect significance of the
18
19 results for cortisol, oxytocin, and psychological stress, except for the group-by-time
20
21 interaction for testosterone which was only marginally significant in the respective model
22
23 [F(2,558)=2.95, $p=.06$, $\eta^2_p = 0.01$]. Controlling for pubertal status did not impact the findings
24
25 besides reducing the strength of the main effect of sex on oxytocin [F(1,159)=2.66, $p=.11$, η^2_p
26
27 =0.02]. Psychiatric comorbidities did not affect cortisol and oxytocin results, while comorbid
28
29 ADHD, SUD and MDD rendered the group-by-time interactions for testosterone marginally
30
31 significant ($p=.06-.10$), and ADHD, ANX and MDD the group effect for psychological stress
32
33 ($p=.05-.13$). CD age-of-onset did not correlate with any stress responsivity measure ($r<-.13$,
34
35 $p>.18$), while CD severity correlated negatively with the AUC_I for cortisol ($r=-.37$, $p<.001$),
36
37 testosterone ($r=-.24$, $p<.001$), and positively with psychological stress ($r=.16$, $p=.01$).
38
39
40
41
42
43
44
45

46 ***Exploratory mediation analyses of environmental risk for CD by psychoneuroendocrine stress responses***

47 In additional exploratory analyses (see Figure 3, Table S3), AUC_I of cortisol was found to
48
49 mediate the relation between prenatal violence exposure and adverse family situation with CD
50
51 status, explaining 7-10% of the total effect. Similar mediation effects were observed for
52
53 cortisol increase (13-15% of the total effect). Cortisol recovery mediated the relationships
54
55 between prenatal smoking, adverse family situation and trauma exposure with CD status (13-
56
57
58
59
60
61
62
63
64
65

16% of the total effect). Oxytocin increase mediated the relation between prenatal smoking and CD, and oxytocin recovery between prenatal smoking and violence with CD (10-13% of the total effect). The AUC_I for psychological stress mediated the relation between adverse family situation and CD (5% of the total effect). No other significant mediating effects were found.

[Figure 3]

Discussion

To our knowledge, this is the first and the largest study to date which comprehensively examines whether females with CD show similarly attenuated HPA-axis stress responses compared to males with CD, and also the first to simultaneously investigate other neuroendocrine systems. Our results replicate and considerably extend previous work of smaller studies in males with CD focusing on cortisol stress response by providing evidence for a diminished neuroendocrine stress responsivity of not only the HPA-axis, but also the HPG-axis and neuropeptide systems in CD. Critically, this neuroendocrine hypo-reactivity to stress was observed in both females and males with CD compared to healthy adolescents. Furthermore, changes in psychoneuroendocrine stress responsivity mediated the relationship between common pre- and postnatal risk factors and CD, suggesting that exposure to early adversity may increase risk for CD partly through its effects on the body's neuroendocrine systems. All analyses controlled for relevant confounders such as smoking, BMI, TSST start time, or medication use (incl. contraceptives). IQ and pubertal status did not substantially affect results. The female CD and HC groups did not differ in menstrual cycle status with most girls being in the luteal phase during which the neuroendocrine stress response is more comparable to that observed in males³⁶.

Individuals with CD differed substantially in their psychoneuroendocrine stress responsivity compared to healthy adolescents. While HCs showed clear cortisol, testosterone, and oxytocin responses to the TSST (comparable to previous reports in healthy adolescents^{8,14,30}), a widespread attenuation of neuroendocrine stress responsivity was found in CD. In line with earlier reports⁶, we observed blunted cortisol stress responsivity in males with CD. Importantly, our results demonstrate that females with CD show similarly attenuated cortisol stress responses as males with CD. As earlier work did not investigate females and males with CD in response to a standardized stress task, our findings are the first to indicate blunted

1 HPA-axis activity as a distinct characteristic of CD independent of sex. Furthermore, as
2 earlier studies on neuroendocrine stress responsivity in CD were restricted to cortisol, our
3
4 results substantially extend previous work by showing comparable attenuations for
5
6 testosterone and oxytocin in both females and males with CD. In line with previous findings
7
8
9 ³⁷, CD age-of-onset did not influence results. In contrast, as CD severity increased,
10
11 psychoneuroendocrine stress responses were more strongly altered (blunted) similar to earlier
12
13 reports ^{38,39} supporting dimensional approaches to understanding CD. Attenuated cortisol and
14
15 oxytocin stress responses were not explained by psychiatric comorbidities such as ADHD,
16
17 PTSD, anxiety, depressive or substance use disorders.
18
19
20
21

22 Our findings of concurrently attenuated steroid hormone and neuropeptide stress
23
24 responses suggest an overall impaired neuroendocrine stress-regulation in females and males
25
26 with CD, which may also impair the individual's ability to cope with stressful situations. Our
27
28 findings of higher psychological stress responsivity in CD compared to HCs support this
29
30 notion. Coordinated stress responsivity of the HPA-axis, HPG-axis and neuropeptide systems
31
32 may facilitate successful management of stressful situations with cortisol activating energy
33
34 resources, testosterone improving performance, and oxytocin reducing feelings of stress and
35
36 anxiety ^{8,14}. As the groups did not differ in baseline psychological stress, our findings suggest
37
38 individuals with CD to be more psychologically affected by stress than HCs. Similar or higher
39
40 rates of negative feelings in children and adolescents with CD in response to stress have been
41
42 reported previously ⁶. Notably, results of post-hoc-comparisons in this study indicate slower
43
44 recovery from psychological stress in CD compared to healthy individuals. The psychological
45
46 stress response appears to be more prolonged in individuals with CD, persisting beyond the
47
48 TSST. Attenuated neuroendocrine stress responsivity may prevent successful adaptation to
49
50 stress as this may normally help the individual to regulate their levels of psychological stress.
51
52 This may relate to emotion regulation difficulties, which have been reported in CD ⁴⁰.
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Interestingly, a similar discrepant pattern of psychoneuroendocrine stress responsivity to the
2 TSST (decreased cortisol, but increased psychological responses) was found in adult females
3
4 with borderline personality disorder, which is characterized by severe emotion dysregulation
5
6
7⁴¹.

8
9
10 Given the widespread psychoneuroendocrine alterations observed in CD,
11 understanding their origins is important. Exposure to adversity has been reported to attenuate
12
13 neuroendocrine stress responsivity^{17–19} and has also been strongly associated with CD¹⁶, as
14
15 replicated here. Thus, we applied mediation analyses to explore the influence of
16
17 psychoneuroendocrine stress responses on the relation between pre- and post-natal risk factors
18
19 and CD. Mediation effects were found for cortisol and oxytocin (both particularly relevant for
20
21 stress regulation) as well as psychological stress responses. Exposure to prenatal
22
23 smoking/violence, adverse family situation, and trauma not only predicted CD, but also
24
25 attenuated cortisol and oxytocin accompanied by higher psychological stress responses. These
26
27 alterations, in turn, predicted CD. Our results indicate neurobiological alterations in CD, such
28
29 as attenuated psychoneuroendocrine stress responses, are associated with early adversity.
30
31 However, given the exploratory design, results need to be replicated. Yet, our findings are in
32
33 line with reports of similar neurobiological mediation effects of structural brain alterations on
34
35 the relation between early adversity and antisocial behavior in adolescents⁴². Attenuated
36
37 neuroendocrine stress responsivity may constitute an underlying mechanism by which
38
39 environmental risks contribute to CD risk driven by an early adaptation to adversity²⁰.
40
41 However, the underlying neural mechanisms, e.g., alterations in brain structure or functioning,
42
43 need to be identified in future studies.
44
45
46
47
48
49
50
51
52
53

54
55 Considering impairments in psychoneuroendocrine stress regulation and associated
56
57 environmental risk factors in the process of treating CD may help to improve individuals'
58
59 stress coping strategies, which may reduce the incidence of CD-related behaviors. In line with
60
61
62
63
64
65

1 this, cortisol responsivity has been shown to predict responses to behavioral interventions in
2 children and adolescents with disruptive behavioral disorders, with blunted stress responsivity
3 linked to poorer treatment outcomes ⁴³. To improve outcomes of interventions for CD, it may
4 be possible to personalize treatments based on an individual's neurobiological characteristics,
5 e.g., by implementing additional pharmacological treatments in those with a high
6 neurobiological risk. However, effects of personalized interventions and pharmacological
7 treatments seeking to normalize neuroendocrine hypo-reactivity are yet to be studied in
8 adolescents with CD.
9

10
11
12
13
14
15
16
17
18
19
20 This study has several strengths. We included a large and representative European
21 sample of females and males with and without CD, the groups being matched for sex, age,
22 and pubertal status, allowing sex-specific analyses. Participants with CD and healthy controls
23 were reliably diagnosed using standardized semi-structured diagnostic interviews according to
24 DSM-IV-TR criteria. Our study is the first to date which investigated psychoneuroendocrine
25 stress responses in females compared to males with CD applying a standardized and widely
26 used laboratory psychosocial stress test procedure (the TSST ^{29,30}). Moreover, we reliably
27 assessed established biomarkers of three major neuroendocrine systems, namely the HPA-axis
28 (cortisol), HPG-axis (testosterone) and neuropeptide (oxytocin) system, while previous work
29 in males with CD has focused on cortisol reactivity alone. Importantly, we also controlled for
30 major confounding variables on neuroendocrine functioning (e.g. smoking, BMI, TSST start
31 time, or medication use). Finally, this is the first study exploring whether neuroendocrine
32 markers mediate the effects of environmental risk factors for CD.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51
52 However, our study also has several limitations. First, data were collected across five
53 European sites, and the sites contributed different sample sizes according to site-specific
54 recruitment possibilities. To ensure comparability, standardized operating procedures were
55 used at each site during all assessments with adherence controlled by external monitors. Site
56
57
58
59
60
61
62
63
64
65

was also included as a covariate in the analyses. Second, the age range was relatively large. Nevertheless, groups were matched for age, and age was included as a covariate. Third, data on oxytocin stress responsivity was obtained in a smaller sample compared to our cortisol and testosterone measures, but still in a relatively large sample (N=170) compared to other neuroendocrine studies. Further, while steroid hormones can pass the blood-brain-barrier, non-invasive peripheral salivary assessment may not fully capture central release of oxytocin. However, salivary oxytocin has been repeatedly reported as a valid, non-stressful (which is especially relevant for research on stress responsivity) assessment in adolescents and adults^{13,14} correlating with its central concentrations⁴⁴. Fourth, the only sex hormone studied here was testosterone, a predominantly male hormone, as work investigating female sex hormone responses to stress in children and adolescents is rare. Although concentrations are lower than in males, testosterone is still an essential part of the female neuroendocrine system. Fifth, storage of saliva samples at -20°C was reported as less optimal than -80°C⁴⁵. However, as storage was similar across groups, possible degradation by storage temperature may only have influenced absolute, rather than relative concentrations. Sixth, pubertal status was assessed via self-report. Future studies may consider additional measures of pubertal development, such as physical examination by pediatricians. Seventh, CD is a heterogeneous disorder characterized by different subtypes (e.g., callous-unemotional traits, childhood- versus adolescent-onset, reactive, proactive, and/or relational aggression)⁴⁶⁻⁴⁸, which may influence neuroendocrine characteristics^{49,50}. Further studies are needed to investigate the impact of different CD subtypes, although CD severity rather than age-of-onset appeared more influential in determining stress responsivity here. Finally, pre- and postnatal risk factors were assessed retrospectively, predominantly relying on parent-report data, and mediation analyses were performed only in an exploratory fashion. Further, at best prospective longitudinal studies investigating overlapping questions are thus needed.

1 In conclusion, this work substantially extends current knowledge about stress
2 responsivity in CD beyond males. It is the first and largest study providing compelling
3 evidence for attenuated stress responsivity in not only males, but also females with CD. Our
4 study not only demonstrates reduced cortisol stress responsivity, but also testosterone and
5 oxytocin hypo-reactivity, in both females and males with CD compared to healthy
6 adolescents. Our results indicate a substantially altered neuroendocrine stress response in CD
7 irrespective of sex. These findings were unrelated to potential confounding factors such as
8 smoking, BMI, TSST start time, medication use (incl. contraceptives), IQ, pubertal status, CD
9 age-of-onset, or site. The discrepancy between lower neuroendocrine, but elevated
10 psychological stress responsivity suggests poorer coordination of neurobiological and
11 emotional processes in CD. Our findings further suggest that neuroendocrine alterations may
12 act as a possible underlying mechanism through which early adversity contributes to risk for
13 CD. Considering neurobiological characteristics and associated environmental risks in
14 personalizing an individual's treatment may help to improve future interventions for CD.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

1. Fairchild G, Hawes DJ, Frick PJ, et al. Conduct disorder. *Nat Rev Dis Prim.* 2019;5(43):1-25. doi:10.1038/s41572-019-0095-y
2. Freitag CM, Konrad K, Stadler C, et al. Conduct disorder in adolescent females-current state of research and study design of the Fem-NAT-CD consortium. *Eur Child Adolesc Psychiatry.* 2018;27:1077-1093.
3. Cappadocia MC, Desrocher M, Pepler D, Schroeder JH. Contextualizing the neurobiology of conduct disorder in an emotion dysregulation framework. *Clin Psychol Rev.* 2009;29(6):506-518. doi:10.1016/j.cpr.2009.06.001
4. Oyola MG, Handa RJ. Hypothalamic–pituitary–adrenal and hypothalamic–pituitary–gonadal axes: sex differences in regulation of stress responsivity. *Stress.* 2017;20(5):476-494. doi:10.1080/10253890.2017.1369523.Hypothalamic
5. Kudielka BM, Gierens A, Hellhammer DH, Wüst S, Schlotz W. Salivary cortisol in ambulatory assessment-some dos, some don'ts, and some open questions. *Psychosom Med.* 2012;74(4):418-431. doi:10.1097/PSY.0b013e31825434c7
6. Fairchild G, Baker E, Eaton S. Hypothalamic-Pituitary-Adrenal Axis Function in Children and Adults with Severe Antisocial Behavior and the Impact of Early Adversity. *Curr Psychiatry Rep.* 2018;20(84):1-9.
7. Pajer K, Gardner W, Rubin RT, Perel J, Neal S. Decreased cortisol levels in adolescent girls with conduct disorder. *Arch Gen Psychiatry.* 2001;58(3):297-302. doi:10.1001/archpsyc.58.3.297
8. Turan B, Tackett JL, Lehtreck MT, Browning WR. Coordination of the cortisol and testosterone responses: A dual axis approach to understanding the response to social status threats. *Psychoneuroendocrinology.* 2015;62:59-68. doi:10.1016/j.psyneuen.2015.07.166

9. Viau V. Functional cross-talk between the hypothalamic-pituitary-gonadal and -adrenal axes. *J Neuroendocrinol.* 2002;14(6):506-513. doi:10.1046/j.1365-2826.2002.00798.x
10. Torner L, Plotsky PM, Neumann ID, de Jong TR. Forced swimming-induced oxytocin release into blood and brain: Effects of adrenalectomy and corticosterone treatment. *Psychoneuroendocrinology.* 2017;77:165-174. doi:10.1016/j.psyneuen.2016.12.006
11. Yildirim BO, Derksen JJL. A review on the relationship between testosterone and life-course persistent antisocial behavior. *Psychiatry Res.* 2012;200:984-1010. doi:10.1016/j.psychres.2012.07.044
12. Neumann ID, Landgraf R. Balance of brain oxytocin and vasopressin: Implications for anxiety, depression, and social behaviors. *Trends Neurosci.* 2012;35(11):649-659. doi:10.1016/j.tins.2012.08.004
13. de Jong TR, Menon R, Bludau A, et al. Salivary oxytocin concentrations in response to running, sexual self-stimulation, breastfeeding and the TSST: The Regensburg Oxytocin Challenge (ROC) study. *Psychoneuroendocrinology.* 2015;62:381-388. doi:10.1016/j.psyneuen.2015.08.027
14. Bernhard A, van der Merwe C, Ackermann K, Martinelli A, Neumann ID, Freitag CM. Adolescent oxytocin response to stress and its behavioral and endocrine correlates. *Horm Behav.* 2018;105:157-165. doi:10.1016/j.yhbeh.2018.08.010
15. Bakker-Huvenaars MJ, Greven CU, Herpers P, et al. Saliva oxytocin, cortisol, and testosterone levels in adolescent boys with autism spectrum disorder, oppositional defiant disorder/conduct disorder and typically developing individuals. *Eur Neuropsychopharmacol.* 2020;30:87-101. doi:10.1016/j.euroneuro.2018.07.097
16. Bernhard A, Martinelli A, Ackermann K, Saure D, Freitag CM. Association of trauma, Posttraumatic Stress Disorder and Conduct Disorder: A systematic review and meta-analysis. *Neurosci Biobehav Rev.* 2018;91:153-169. doi:10.1016/j.neubiorev.2016.12.019

17. Koss KJ, Gunnar MR. Early adversity, the hypothalamic–pituitary–adrenocortical axis, and child psychopathology. *J Child Psychol Psychiatr.* 2018;59(4):327-346. doi:10.1111/jcpp.12784
18. Bunea IM, Szentágotai-Tatar A, Miu AC. Early-life adversity and cortisol response to social stress: a meta-analysis. *Transl Psychiatry.* 2017;7(1274):1-8. doi:10.1038/s41398-017-0032-3
19. Tobon AL, Newport DJ, Nemeroff CB. The Role of Oxytocin in Early Life Adversity and Later Psychopathology: a Review of Preclinical and Clinical Studies. *Curr Treat Options Psych.* 2018;5:401-415. doi:10.1007/s40501-018-0158-9
20. Del Giudice M, Ellis BJ, Shirtcliff EA. The Adaptive Calibration Model of stress responsivity. *Neurosci Biobehav Rev.* 2011;35(7):1562-1592. doi:10.1016/j.neubiorev.2010.11.007.The
21. Fragakaki I, Cima M, Granic I. The role of trauma in the hormonal interplay of cortisol, testosterone, and oxytocin in adolescent aggression. *Psychoneuroendocrinology.* 2018;88:24-37. doi:10.1016/j.psyneuen.2017.11.005
22. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV-TR).* Washington, DC: American Psychiatric Association; 2000.
23. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. *J Am Acad Child Adolesc Psychiatry.* 1997;36(7):980-988. doi:10.1097/00004583-199707000-00021
24. Wechsler D. *Wechsler Intelligence Scale for Children—Fourth Edition (WISC-IV).* San Antonio: TX: Psychological Corporation; 2003.
25. Wechsler D. *Wechsler Adult Intelligence Scale—Fourth Edition (WAIS-IV).* San Antonio: TX: NCS Pearson 22; 2008.

26. Wechsler D. *Wechsler Abbreviated Scale of Intelligence*. San Antonio: TX: Psychological Corporation; 1999.
27. Organisation for Economic Co-operation and Development. *Classifying Educational Programmes: Manual for ISCED-97 Implementation in OECD Countries*. (OECD, ed.). Paris; 1999.
28. Petersen AC, Crockett L, Richards M, Boxer A. A Self-Report Measure of Pubertal Status: Reliability, Validity, and Initial Norms. *J Youth Adolesc*. 1988;17(2):117-133.
29. Kirschbaum C, Pirke KM, Hellhammer DH. The 'Trier Social Stress Test'-A Tool for Investigating Psychobiological Stress Responses in a Laboratory Setting. *Neuropsychobiology*. 1993;28:76-81.
30. Allen AP, Kennedy PJ, Cryan JF, Dinan TG, Clarke G. Biological and psychological markers of stress in humans: Focus on the Trier Social Stress Test. *Neurosci Biobehav Rev*. 2014;38:94-124. doi:10.1016/j.neubiorev.2013.11.005
31. Hellhammer J, Schubert M. The physiological response to Trier Social Stress Test relates to subjective measures of stress during but not before or after the test. *Psychoneuroendocrinology*. 2012;37(1):119-124. doi:10.1016/j.psyneuen.2011.05.012
32. Salimetrics. Calculating inter-and intra-assay-coefficients of variability. <https://salimetrics.com/calculating-inter-and-intra-assay-coefficients-of-variability/>. 2021.
33. Delaney HD, Maxwell SE. On using analysis of covariance in repeated measures designs. *Multivariate Behav Res*. 1981;16:105-123.
34. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. 2nd ed. Hillsdale: Lawrence Earlbaum Associates; 1988.
35. Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. *Behav Res Methods*. 2008;40(3):879-891. doi:10.3758/BRM.40.3.879

36. Kajantie E, Phillips DIW. The effects of sex and hormonal status on the physiological response to acute psychosocial stress. *Psychoneuroendocrinology*. 2006;31(2):151-178. doi:10.1016/j.psyneuen.2005.07.002
37. Fairchild G, Goozen SHM Van, Stollery SJ, et al. Cortisol Diurnal Rhythm and Stress Reactivity in Male Adolescents with Early-Onset or Adolescence-Onset Conduct Disorder. 2008. doi:10.1016/j.biopsycho.2008.05.022
38. de Vries-Bouw M, Jansen L, Vermeiren R, Doreleijers T, van de Ven P, Popma A. Concurrent attenuated reactivity of alpha-amylase and cortisol is related to disruptive behavior in male adolescents. *Horm Behav*. 2012;62:77-85. doi:10.1016/j.yhbeh.2012.05.002
39. Schoorl J, Rijn S van, Wied M de, van Goozen S, Swaab H. The role of anxiety in cortisol stress response and cortisol recovery in boys with oppositional defiant disorder/conduct disorder. *Psychoneuroendocrinology*. 2016;73:217-223. doi:10.1016/j.psyneuen.2016.08.007
40. Kohls G, Baumann S, Gundlach M, et al. Investigating Sex Differences in Emotion Recognition, Learning, and Regulation Among Youths With Conduct Disorder. *J Am Acad Child Adolesc Psychiatry*. 2020;59(2):263-273. doi:10.1016/j.jaac.2019.04.003
41. Nater UM, Bohus M, Abbruzzese E, et al. Increased psychological and attenuated cortisol and alpha-amylase responses to acute psychosocial stress in female patients with borderline personality disorder. *Psychoneuroendocrinology*. 2010;35(10):1565-1572. doi:10.1016/j.psyneuen.2010.06.002
42. Mackey S, Chaarani B, Kan KJ, et al. Brain regions related to impulsivity mediate the effects of early adversity on antisocial behavior. *Biol Psychiatry*. 2017;82(4):275-282.
43. Schoorl J, Rijn S Van, Wied M De, van Goozen SHM, Swaab H. Neurobiological stress responses predict aggression in boys with oppositional defiant disorder/conduct disorder: a 1 - year follow - up intervention study. *Eur Child Adolesc Psychiatry*.

2017;26(7):805-813. doi:10.1007/s00787-017-0950-x

44. Martin J, Kagerbauer SM, Gempt J, Podtschaske A, Hapfelmeier A, Schneider G. Oxytocin levels in saliva correlate better than plasma levels with concentrations in the cerebrospinal fluid of patients in neurocritical care. *J Neuroendocrinol.* 2018;30:e12596. doi:10.1111/jne.12596
45. Granger DA, Shirtcliff EA, Booth A, Kivlighan KT, Schwartz EB. The “trouble” with salivary testosterone. *Psychoneuroendocrinology.* 2004;29:1229-1240. doi:10.1016/j.psyneuen.2004.02.005
46. Ackermann K, Kirchner M, Bernhard A, et al. Relational Aggression in Adolescents with Conduct Disorder: Sex Differences and Behavioral Correlates. *J Abnorm Child Psychol.* 2019;47(10):1625-1637. doi:10.1007/s10802-019-00541-6
47. Frick PJ, White SF. Research Review: The importance of callous- unemotional traits for developmental models of aggressive and antisocial behavior. *J Child Psychol Psychiatry.* 2008;49(4):359-375. doi:10.1111/j.1469-7610.2007.01862.x
48. Kempes M, Matthys W, De Vries H, Van Engeland H. Reactive and proactive aggression in children. A review of theory, findings and the relevance for child and adolescent psychiatry. *Eur Child Adolesc Psychiatry.* 2005;14(1):11-19. doi:10.1007/s00787-005-0432-4
49. van Hazebroek BCM, Wermink H, van Domburgh L, de Keijser JW, Hoeve M, Popma A. Biosocial studies of antisocial behavior: A systematic review of interactions between peri/prenatal complications, psychophysiological parameters, and social risk factors. *Aggress Violent Behav.* 2019;47(2019):169-188. doi:10.1016/j.avb.2019.02.016
50. Levy T, Bloch Y, Bar-Maisels M, et al. Salivary oxytocin in adolescents with conduct problems and callous-unemotional traits. *Eur Child Adolesc Psychiatry.* 2015;24(12):1543-1551. doi:10.1007/s00787-015-0765-6

Table/Figure legends

Table 1. Sample characteristics, risk factors, comorbidities, and baseline psychoneuroendocrine levels in conduct disorder (CD) participants compared to healthy controls (HCs).

Note. ^aFor definition of pubertal categories, see *Methods*. ^bNon-stimulants include atomoxetine medication. 'Other' includes asthma medication, painkiller, or vitamin preparation. Participants may have been prescribed more than one medication category. ^cRates of lifetime anxiety disorder cover lifetime panic disorder, separation anxiety disorder, avoidant disorder, simple phobia, social phobia, agoraphobia, overanxious disorder, and generalized anxiety disorder. ^dAccording to the trauma definition within the PTSD section of the K-SADS-PL (for further details see *Methods*).

Table 2. Results of repeated-measures ANCOVA of psychoneuroendocrine stress responses per group and sex.

Note. Repeated measure analyses of co-variance (rmANCOVA) with group (CD vs. HCs) and sex (female vs. male) as between-subjects factors, and time as a within-subject factor, respectively, controlled for major confounders (see Statistical Analyses). Where necessary, Greenhouse Geisser corrections were applied, but for clarity uncorrected degrees of freedom are reported here. η^2_p =partial eta squared. ^aBonferroni-corrected post-hoc pairwise comparisons indicated a slower rate of recovery from stress in male compared to female HCs (Mean change +10 to +55 minute [SD]: female HCs 0.16 [0.03], $p<.001$, male HCs -0.002 [0.04], $p=1.00$, no significant differences between females and males with CD, $p>.22$). CD=Conduct Disorder, HCs=Healthy Controls.

1
2
3 **Figure 1.** Overview of stress test procedure.
4

5
6 *Note.* After a relaxation period in a comfortable room (Room A), the baseline assessment was
7
8 taken, before participants entered a sparsely equipped experimental room (Room B). The
9
10 Trier Social Stress Test (TSST) involved four components: task introduction, preparation
11
12 time, speech task, and an age-adapted mental arithmetic task. For more information see
13
14 *Methods.* CORT=Cortisol, OXT=Oxytocin, TEST=Testosterone, VAS=Visual Analogue
15
16 Scale.
17
18
19
20

21 **Figure 2.** Psychoneuroendocrine stress responses during the Trier Social Stress Test in
22
23 conduct disorder (CD) participants compared to healthy controls (HCs).
24

25
26 *Note.* fCD=female CD, fHCs=female HCs, mCD=male CD, mHCs=male HCs. Significant
27
28 difference of respective value between CD and HCs: * $p<.05$, ** $p<.01$, *** $p<.001$
29
30

31 **Figure 3.** Psychoneuroendocrine stress measures as mediators of the relation between early
32
33 environmental risk factors and conduct disorder (CD).
34
35

36
37 *Note.* Numbers in brackets refer to 95% confidence intervals. * $p<.05$, ** $p<.01$, *** $p<.001$.
38
39 AUC_I=area under the curve with respect to increase.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1. Sample characteristics, comorbidities, risk factors, and baseline psychoneuroendocrine levels in conduct disorder (CD) participants compared to healthy controls (HCs).

	Females (N=186)		Males (N=104)		Group	Sex	Group x sex
	CD (N=82)	HCs (N=104)	CD (N=48)	HCs (N=56)			
	Mean (SD) or N (%)				<i>p</i>	<i>p</i>	<i>p</i>
Age (years)	14.83 (1.5)	14.58 (2.1)	14.54 (2.1)	14.88 (2.1)	.87	.98	.22
Estimated Full-Scale IQ	97.32 (12.8)	104.33 (12.1)	101.21 (12.6)	105.75 (11.7)	<.001	.08	.42
Parental educational status	3.00 (1.0)	3.88 (1.1)	3.30 (0.7)	3.65 (0.9)	<.001	.78	.04
Body Mass Index	23.63 (6.5)	20.67 (3.9)	22.07 (4.0)	20.92 (3.6)	<.01	.27	.13
Start time Trier Social Stress Test (hh:mm)	15:08 (00:58)	15:16 (00:53)	15:07 (00:51)	14:56 (00:51)	.87	.12	.17
Pubertal Status ^a					.13	<.001	
Early-pubertal	1 (1.2)	2 (1.9)	10 (20.8)	12 (21.4)			
Mid-pubertal	5 (6.1)	19 (18.3)	13 (27.1)	17 (30.4)			
Late-pubertal	57 (69.5)	54 (51.9)	23 (47.9)	24 (42.9)			
Post-pubertal	19 (23.2)	29 (27.9)	2 (4.2)	3 (5.4)			
Current smoking	51 (62.2)	7 (6.7)	25 (52.1)	9 (16.1)	<.001	.79	
Any medication ^b	48 (58.5)	12 (11.5)	10 (20.8)	2 (3.6)	<.001	<.001	
Neuroleptics	5 (6.1)	0 (0.0)	3 (6.3)	0 (0.0)	<.01	.92	
Stimulants	12 (14.6)	0 (0.0)	5 (10.4)	0 (0.0)	<.001	.57	
Non-stimulants	0 (0.0)	0 (0.0)	2 (4.2)	0 (0.0)	.12	.06	
SSRIs/antidepressants	5 (6.1)	0 (0.0)	2 (4.2)	0 (0.0)	<.01	.68	
Contraceptives	32 (47.1)	10 (13.5)	0 (0.0)	0 (0.0)	<.001		
Other	9 (11.0)	7 (6.0)	2 (4.2)	2 (3.6)	<.05	.35	
Comorbidities							
Lifetime ADHD	31 (37.8)	0 (0.0)	28 (58.3)	0 (0.0)	<.001	.04	
Lifetime substance use disorder	18 (22.0)	0 (0.0)	14 (29.2)	1 (1.8)	<.001	.22	
Lifetime anxiety disorder ^c	18 (22.0)	2 (1.9)	17 (35.4)	2 (3.6)	<.001	.07	
Lifetime depressive disorder	35 (42.7)	4 (3.8)	9 (18.8)	0 (0.0)	<.001	<.01	
Lifetime PTSD	11 (13.4)	1 (1.0)	5 (10.4)	1 (1.8)	<.001	.82	
Pre- and postnatal risk factors							
Prenatal smoking	27 (40.9)	15 (16.1)	19 (48.7)	8 (15.7)	<.001	.54	
Prenatal violence	17 (25.4)	5 (5.4)	7 (18.4)	2 (2.4)	<.001	.42	
Adverse family situation					<.001	.99	
Either disharmony or isolation	25 (39.1)	16 (17.0)	11 (29.7)	12 (24.5)			
Both disharmony and isolation	20 (31.3)	3 (3.2)	11 (29.7)	1 (2.0)			
Number of traumatic events experienced ^d	2.78 (2.0)	1.08 (1.2)	2.13 (1.9)	1.46 (1.2)	<.001	.49	<.01
Baseline psychoneuroendocrine levels							
Cortisol (nmol/l)	2.91 (1.3)	2.64 (1.8)	3.22 (2.0)	3.35 (2.1)	.74	.02	.36
Testosterone (pg/ml)	39.64 (17.1)	34.30 (14.2)	60.40 (31.3)	58.12 (32.0)	.17	<.001	.59
Oxytocin (pg/ml)	1.37 (0.5)	1.39 (0.7)	1.07 (0.3)	1.27 (0.6)	.20	.02	.34
Psychological stress	1.51 (2.5)	1.21 (2.0)	1.43 (1.7)	0.94 (1.7)	.11	.48	.69

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 2. Results of repeated-measures ANCOVA of psychoneuroendocrine stress responses per group and sex.

repeated measures ANCOVA	Cortisol				Testosterone				Oxytocin				Psychological stress			
	<i>df</i>	<i>F</i>	<i>p</i>	η^2_p	<i>df</i>	<i>F</i>	<i>p</i>	η^2_p	<i>df</i>	<i>F</i>	<i>p</i>	η^2_p	<i>df</i>	<i>F</i>	<i>p</i>	η^2_p
Time	4, 1120	6.45	<.01	0.02	2, 560	6.65	<.01	0.02	2, 320	6.33	<.01	0.04	7, 1988	31.51	<.001	0.10
Group	1, 280	11.55	<.01	0.04	1, 280	0.13	.72	0.00	1, 160	1.03	.31	0.00	1, 284	8.21	<.01	0.03
Sex	1, 280	0.03	.87	0.00	1, 280	40.39	<.001	0.13	1, 160	6.68	.01	0.04	1, 284	2.61	.11	0.00
Group x time	4, 1120	11.08	<.001	0.04	2, 560	3.90	.02	0.01	2, 320	4.28	.02	0.03	7, 1988	0.42	.76	0.00
Sex x time	4, 1120	1.73	.17	0.00	2, 560	1.67	.19	0.00	2, 320	0.65	.52	0.00	7, 1988	1.93	.12	0.00
Group x sex x time	4, 1120	1.28	.28	0.00	2, 560	4.30	.02 ^a	0.02	2, 320	0.08	.92	0.00	7, 1988	0.76	.53	0.00

**MANUSCRIPT SUBMISSION FORM—*JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY*
and *JAACAP Connect***

Section 1: Instructions. A copy of this form, with signatures included from **ALL authors** on the manuscript, must accompany every new manuscript submission before it will be considered for publication. Please fully complete to eliminate delays in submission. Use an additional form if there are more than 10 authors. Please include completed form and attached page during the submission process. If you are unable to do so, fax the completed form and attached page to the Editorial Office at 202.587.9673.

Section 2: Manuscript Information.

Manuscript Title: Neuroendocrine stress response in female and male adolescents with Conduct Disorder and associated early adversity

Complete Author List (in order): Anka Bernhard, Katharina Ackermann, Anne Martinelli, Leonora Vllasaliu, Karen Gonzalez-Madruga, Molly Batchelor, Nora Raschle, Helena Oldenhof, Lucres Jansen, Gregor Kohls, Kerstin Konrad, Arne Popma, Christina Stadler, Graeme Fairchild & Christine M. Freitag

Corresponding Author Name: Anka Bernhard

Section 3: On an attached page, please list the funding, acknowledgments, and financial disclosures of all authors.

Section 4: Acknowledgments. By signing below, I acknowledge my acceptance to and/or certification of the following information.

✓ **Approval of the Submitted Work and Acknowledgment of Role of Corresponding Author.** Submission of an article certifies that the work described is original; has been written by the stated authors; has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>); is not under consideration for publication elsewhere; that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out; and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.

I agree that the corresponding author (named above) shall be the sole correspondent with the Editorial Office on all matters related to this submission. In the event of acceptance, I designate the corresponding author as the responsible party for all communications with the journal's publisher related to this work, including review and correction of the typeset proof. I understand that once a manuscript is submitted, no substantial changes to the content will be allowed.

✓ **Authorship Contribution.** I am able to identify which coauthors are responsible for specific other parts of the work, and I have confidence in the integrity of the contributions of my coauthors. I warrant that I qualify for authorship based on the following criteria:

1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; **AND**
2. Drafting the work or revising it critically for important intellectual content; **AND**
3. Final approval of the version to be published; **AND**
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

✓ **Financial and Material Support.** All sources of grant or other financial support, as well as any material support, are listed on the page attached to this form and on the title page of the submitted manuscript. If no funding was received, please state this.

✓ **Author Conflicts of Interest/Disclosures.** To my knowledge, all of my possible conflicts of interest and those of my coauthors, financial or otherwise, including direct or indirect financial or personal relationships, interests, and affiliations, whether or not directly related to the subject of the paper, that have occurred over the last two years, or that are expected in the foreseeable future are listed on the page attached to this form and on the title page of the submitted manuscript. Disclosure includes, but is not limited to, grants or research funding, employment, affiliations, patents (in preparation, filed, or granted), inventions, speakers' bureaus, honoraria, consultancies, royalties, stock options/ownership, or expert testimony. If an author has no conflicts of interest to declare, this must be stated explicitly. For example, Dr. Stearns reports no biomedical financial interests or potential conflicts of interest.

✓ **Transfer of Copyright.** To the extent that this work was not performed by employees of the U.S. Federal Government, I agree to transfer copyright to the American Academy of Child and Adolescent Psychiatry upon acceptance of this submission for publication in the Journal. I authorize the corresponding author to sign the Journal Publishing Agreement on my behalf.

Author Name (Printed)	Author Signature	Date
1. <u>Anka Bernhard</u>	<u>Anka Bernhard</u> <small>Digital unterschrieben von Anka Bernhard Datum: 2021.01.14 12:57:55 +01'00'</small>	<u>14.01.2021</u>
2. <u>Katharina Ackermann</u>	<u>Katharina Ackermann</u> <small>Digital unterschrieben von Katharina Ackermann Datum: 2021.01.14 13:06:43 +01'00'</small>	<u>14.01.2021</u>
3. <u>Anne Martinelli</u>	<u>Anne Martinelli</u> <small>Digital unterschrieben von Anne Martinelli Datum: 2021.01.14 12:59:22 +01'00'</small>	<u>14.01.2021</u>
4. <u>Leonora Vllasaliu</u>	<u>Leonora Vllasaliu</u> <small>Digital unterschrieben von Leonora Vllasaliu Datum: 2021.01.14 13:11:28 +01'00'</small>	<u>14.01.2021</u>
5. <u>Karen Gonzalez-Madruga</u>	<u>Karen Gonzalez-Madruga</u> <small>Digital unterschrieben von Karen Gonzalez-Madruga Datum: 2021.01.14 15:21:34 +01'00'</small>	<u>14.01.2021</u>
6. <u>Molly Batchelor</u>	<u>Molly Batchelor</u> <small>Digital unterschrieben von Molly Batchelor Datum: 2021.01.14 15:24:23 +01'00'</small>	<u>14.01.2021</u>
7. <u>Nora Raschle</u>	<u>Nora Raschle</u> <small>Digital unterschrieben von Nora Raschle Datum: 2021.01.14 16:03:28 +01'00'</small>	<u>14.01.2021</u>
8. <u>Helena Oldenhof</u>	<u>Helena Oldenhof</u> <small>Digital unterschrieben von Helena Oldenhof Datum: 2021.01.15 10:20:58 +01'00'</small>	<u>15.01.2021</u>
9. <u>Lucres Jansen</u>	<u>Lucres Jansen</u> <small>Digital unterschrieben von Lucres Jansen Datum: 2021.01.15 10:23:30 +01'00'</small>	<u>15.01.2021</u>
10. <u>Gregor Kohls</u>	<u>Gregor Kohls</u> <small>Digital unterschrieben von Gregor Kohls Datum: 2021.01.15 11:15:30 +01'00'</small>	<u>15.01.2021</u>

**MANUSCRIPT SUBMISSION FORM—*JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY*
and *JAACAP Connect***

Section 1: Instructions. A copy of this form, with signatures included from **ALL authors** on the manuscript, must accompany every new manuscript submission before it will be considered for publication. Please fully complete to eliminate delays in submission. Use an additional form if there are more than 10 authors. Please include completed form and attached page during the submission process. If you are unable to do so, fax the completed form and attached page to the Editorial Office at 202.587.9673.

Section 2: Manuscript Information.

Manuscript Title: Neuroendocrine stress response in female and male adolescents with Conduct Disorder and associated early adversity

Complete Author List (in order): Anka Bernhard, Katharina Ackermann, Anne Martinelli, Leonora Vllasaliu, Karen Gonzalez-Madruga, Molly Batchelor, Nora Raschle, Helena Oldenhof, Lucres Jansen, Gregor Kohls, Kerstin Konrad, Arne Popma, Christina Stadler, Graeme Fairchild & Christine M. Freitag

Corresponding Author Name: Anka Bernhard

Section 3: On an attached page, please list the funding, acknowledgments, and financial disclosures of all authors.

Section 4: Acknowledgments. By signing below, I acknowledge my acceptance to and/or certification of the following information.

✓ **Approval of the Submitted Work and Acknowledgment of Role of Corresponding Author.** Submission of an article certifies that the work described is original; has been written by the stated authors; has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>); is not under consideration for publication elsewhere; that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out; and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.

I agree that the corresponding author (named above) shall be the sole correspondent with the Editorial Office on all matters related to this submission. In the event of acceptance, I designate the corresponding author as the responsible party for all communications with the journal's publisher related to this work, including review and correction of the typeset proof. I understand that once a manuscript is submitted, no substantial changes to the content will be allowed.

✓ **Authorship Contribution.** I am able to identify which coauthors are responsible for specific other parts of the work, and I have confidence in the integrity of the contributions of my coauthors. I warrant that I qualify for authorship based on the following criteria:

1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; **AND**
2. Drafting the work or revising it critically for important intellectual content; **AND**
3. Final approval of the version to be published; **AND**
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

✓ **Financial and Material Support.** All sources of grant or other financial support, as well as any material support, are listed on the page attached to this form and on the title page of the submitted manuscript. If no funding was received, please state this.

✓ **Author Conflicts of Interest/Disclosures.** To my knowledge, all of my possible conflicts of interest and those of my coauthors, financial or otherwise, including direct or indirect financial or personal relationships, interests, and affiliations, whether or not directly related to the subject of the paper, that have occurred over the last two years, or that are expected in the foreseeable future are listed on the page attached to this form and on the title page of the submitted manuscript. Disclosure includes, but is not limited to, grants or research funding, employment, affiliations, patents (in preparation, filed, or granted), inventions, speakers' bureaus, honoraria, consultancies, royalties, stock options/ownership, or expert testimony. If an author has no conflicts of interest to declare, this must be stated explicitly. For example, Dr. Stearns reports no biomedical financial interests or potential conflicts of interest.

✓ **Transfer of Copyright.** To the extent that this work was not performed by employees of the U.S. Federal Government, I agree to transfer copyright to the American Academy of Child and Adolescent Psychiatry upon acceptance of this submission for publication in the Journal. I authorize the corresponding author to sign the Journal Publishing Agreement on my behalf.

Author Name (Printed)	Author Signature	Date
1. <u>Kerstin Konrad</u>	<u>Kerstin Konrad</u> <small>Digital unterschrieben von Kerstin Konrad Datum: 2021.01.15 10:15:37 +01'00'</small>	<u>15.01.2021</u>
2. <u>Arne Popma</u>	<u>Arne Popma</u> <small>Digital unterschrieben von Arne Popma Datum: 2021.01.15 12:23:38 +01'00'</small>	<u>15.01.2021</u>
3. <u>Christina Stadler</u>	<u>Christina Stadler</u> <small>Digital unterschrieben von Christina Stadler Datum: 2021.01.14 16:36:22 +01'00'</small>	<u>14.01.2021</u>
4. <u>Graeme Fairchild</u>	<u>Graeme Fairchild</u> <small>Digital unterschrieben von Graeme Fairchild Datum: 2021.01.14 15:25:15 +01'00'</small>	<u>14.01.2021</u>
5. <u>Christine M. Freitag</u>	<u>Christine M. Freitag</u> <small>Digital unterschrieben von Christine M. Freitag Datum: 2021.01.14 13:15:19 +01'00'</small>	<u>14.01.2021</u>
6. _____	_____	_____
7. _____	_____	_____
8. _____	_____	_____
9. _____	_____	_____
10. _____	_____	_____

Figure 1















Figure 2

A1. Cortisol stress response per group**A2. Cortisol stress response per group x sex****B1. Testosterone stress response per group****B2. Testosterone stress response per group x sex****C1. Oxytocin stress response per group****C2. Oxytocin stress response per group x sex****D1. Psychological stress response per group****D2. Psychological stress response per group x sex**


Psychoneuroendocrinological assessment points

Figure 3



A. Cortisol



B. Psychological stress



C. Oxytocin



Supplemental information for

*“Neuroendocrine stress responses in female and male adolescents with Conduct Disorder
and associated early adversity”*

Table S1. Number of participants per group and sex across sites.

	Females		Males		Σ N	group <i>p</i>	sex <i>p</i>
	CD	HCS	CD	HCS			
	N	N	N	N			
Total sample						.01	<.001
Frankfurt am Main, Germany	29	49	34	32	144		
Aachen, Germany	13	2	3	3	21		
Amsterdam, The Netherlands	15	14	0	0	29		
Southampton, United Kingdom	16	16	8	16	56		
Basel, Switzerland	9	23	3	5	40		
Σ	82	104	48	56	290		
Oxytocin subsample						.08	<.001
Frankfurt am Main, Germany	26	30	29	27	112		
Aachen, Germany	8	0	2	3	13		
Amsterdam, The Netherlands	7	14	0	0	21		
Southampton, United Kingdom	4	5	2	8	19		
Basel, Switzerland	0	0	2	3	5		
Σ	45	49	35	41	170		

Note. CD=Conduct Disorder, HCS=healthy controls.

Table S2. Sample characteristics, comorbidities, and risk factors in Conduct Disorder (CD) participants compared to healthy controls (HCs) for the oxytocin subsample.

	Females (N=94)		Males (N=76)		Group	Sex	Group x sex
	CD (N=45)	HCs (N=49)	CD (N=35)	HCs (N=41)			
	Mean (SD) or N (%)				<i>p</i>	<i>p</i>	<i>p</i>
Age (years)	14.51 (1.5)	14.53 (2.01)	14.34 (2.1)	14.59 (2.00)	.66	.85	.70
Estimated Full-Scale IQ	95.02 (11.9)	101.53 (12.6)	102.43 (12.6)	108.37 (12.0)	<.01	<.001	.88
Parental educational status	3.06 (1.1)	3.79 (1.1)	3.34 (0.7)	3.74 (1.0)	<.01	.46	.30
Body Mass Index	24.30 (8.0)	20.31 (4.1)	21.78 (4.2)	20.48 (3.5)	<.01	.15	.10
Start time Trier Social Stress Test (hh:mm)	15:04 (00:49)	15:08 (00:33)	15:24 (00:30)	14:59 (00:42)	.09	.39	.02
Pubertal Status					.28	<.001	
Early-pubertal	0 (0.0)	1 (2.0)	8 (22.9)	12 (29.3)			
Mid-pubertal	3 (6.7)	9 (18.4)	9 (25.7)	11 (26.8)			
Late-pubertal	33 (73.3)	27 (55.1)	18 (51.4)	17 (41.5)			
Post-pubertal	9 (20.0)	12 (24.5)	0 (0.0)	1 (2.4)			
Current smoking	25 (55.6)	1 (2.0)	18 (51.4)	7 (17.1)	<.001	.46	
Any medication ^a	28 (62.2)	7 (14.3)	9 (25.7)	2 (4.9)	<.001	<.01	
Neuroleptics	4 (8.9)	0 (0.0)	3 (8.6)	0 (0.0)	<.01	.92	
Stimulants	8 (17.8)	0 (0.0)	5 (14.3)	0 (0.0)	<.001	.64	
Non-stimulants	0 (0.0)	0 (0.0)	1 (2.9)	0 (0.0)	.29	.27	
SSRIs/antidepressants	4 (8.9)	0 (0.0)	2 (5.7)	0 (0.0)	<.01	.57	
Contraceptives	18 (53.8)	5 (14.3)	0 (0.0)	0 (0.0)	<.01		
Other	7 (15.6)	7 (6.0)	1 (2.9)	2 (4.9)	.28	.10	
Comorbidities							
Lifetime ADHD	16 (35.6)	0 (0.0)	22 (62.9)	0 (0.0)	<.001	.06	
Lifetime substance use disorder	10 (22.2)	0 (0.0)	11 (31.4)	1 (2.4)	<.001	.32	
Lifetime anxiety disorder ^b	11 (24.4)	2 (4.1)	15 (42.9)	2 (4.9)	<.001	.15	
Lifetime depressive disorder	21 (46.7)	2 (4.1)	8 (22.9)	0 (0.0)	<.001	.02	
Lifetime PTSD	8 (17.8)	0 (0.0)	5 (14.3)	1 (2.4)	<.001	.89	
Pre- and postnatal risk factors							
Prenatal smoking	12 (36.4)	6 (14.6)	14 (46.7)	4 (10.3)	<.001	.81	
Prenatal violence	11 (30.6)	3 (7.3)	6 (20.7)	2 (5.1)	<.01	.28	
Adverse family situation					<.001	.65	
Either disharmony or isolation	10 (29.4)	7 (17.1)	8 (28.6)	11 (28.9)			
Both disharmony and isolation	12 (35.3)	1 (2.4)	8 (28.6)	1 (2.6)			
Number of traumatic events experienced	2.80 (1.9)	1.14 (1.2)	1.94 (1.7)	1.37 (1.2)	<.001	.18	.02

Note. ^a“Non-stimulants” include atomoxetine, “Other” medication includes for example asthma medication, painkiller, or vitamin preparation. Participants may have reported use of more than one medication category, thus the numbers do not sum up to 100%. ^bRates of lifetime anxiety

disorder cover lifetime panic disorder, separation anxiety disorder, avoidant disorder, simple phobia, social phobia, agoraphobia, overanxious disorder or generalized anxiety disorder.

Table S3. Psychoneuroendocrinological stress measures as mediators of environmental risk and comorbid psychiatric disorders on Conduct Disorder.

	Direct effect (X→Y)	<i>p</i>	Direct effect (X→M)	<i>p</i>	Direct effect (M→Y)	<i>p</i>	Indirect effect (X→M→Y)	95% CI [LB; UB]	Total effect	<i>p</i>	Proportion of total effect mediated [%]
AUC_I											
Cortisol											
Prenatal smoking	1.43	<.001	-1.53	.29	-0.08	<.01	0.12	[-0.10; 0.37]	1.54	<.001	7.64
Prenatal violence	1.72	<.01	-2.88	.15	-0.07	<.01	0.19	[0.01; 0.51]	1.91	<.01	9.80
Adverse family situation	1.46	<.001	-1.88	.04	-0.06	<.01	0.12	[0.02; 0.27]	1.57	<.001	7.42
Trauma exposure	0.45	<.001	-0.30	.42	-0.08	<.001	0.02	[-0.03; 0.09]	0.47	<.001	5.12
Testosterone											
Prenatal smoking	1.51	<.001	0.52	.83	-0.04	<.01	-0.02	[-0.21; 0.16]	1.49	<.001	1.27
Prenatal violence	1.82	<.01	-0.70	.83	-0.04	<.01	0.03	[-0.20; 0.21]	1.85	<.01	1.35
Adverse family situation	1.49	<.001	-2.06	.19	-0.03	.06	0.05	[-0.02; 0.17]	1.54	<.001	3.43
Trauma exposure	0.45	<.001	-0.12	.85	-0.04	<.01	0.004	[-0.05; 0.06]	0.45	<.001	0.92
Oxytocin											
Prenatal smoking	1.53	<.01	-0.29	.10	-0.44	.19	0.13	[-0.01; 0.47]	1.65	<.001	7.70
Prenatal violence	1.91	<.01	-0.20	.35	-0.39	.20	0.08	[-0.08; 0.40]	1.98	<.01	3.86
Adverse family situation	1.33	<.001	-0.05	.63	-0.40	.21	0.02	[-0.07; 0.19]	1.36	<.001	1.61
Trauma exposure	0.38	.01	0.00	.98	-0.38	.17	0.001	[-0.05; 0.04]	0.38	<.001	0.26
Psychological stress											
Prenatal smoking	1.49	<.001	0.58	.67	0.06	<.001	0.03	[-0.12; 0.21]	1.52	<.001	2.10
Prenatal violence	1.64	<.001	4.05	.03	0.05	<.01	0.19	[-0.03; 0.55]	1.83	<.001	10.57
Adverse family situation	1.50	<.001	2.07	.01	0.04	.02	0.09	[0.004; 0.23]	1.59	<.001	5.41
Trauma exposure	0.54	<.001	1.20	<.001	0.03	.07	0.03	[-0.01; 0.08]	0.57	<.001	5.15
INCREASE											
Cortisol											
Prenatal smoking	1.40	<.001	-0.82	.16	-0.26	<.001	0.22	[-0.03; 0.58]	1.61	<.001	13.42
Prenatal violence	1.66	<.01	-1.50	.06	-0.19	<.001	0.28	[0.04; 0.83]	1.94	<.01	14.47
Adverse family situation	1.42	<.001	-1.02	<.01	-0.21	<.01	0.22	[0.08; 0.51]	1.64	<.001	13.23
Trauma exposure	0.41	<.001	-0.24	.11	-0.23	<.001	0.06	[-0.01; 0.15]	0.47	<.001	11.85
Testosterone											
Prenatal smoking	1.52	<.001	0.38	.82	-0.06	<.01	-0.02	[-0.24; 0.19]	1.50	<.001	1.56
Prenatal violence	1.74	<.01	-1.73	.44	-0.06	<.01	0.10	[-0.10; 0.36]	1.84	<.01	5.43
Adverse family situation	1.49	<.001	-1.55	.14	-0.05	.01	0.07	[-0.01; 0.24]	1.57	<.001	4.79
Trauma exposure	0.43	<.001	-0.52	.21	-0.06	<.01	0.03	[-0.02; 0.09]	0.46	<.001	6.85
Oxytocin											
Prenatal smoking	1.47	<.01	-0.27	.06	-0.84	.11	0.22	[0.03; 0.78]	1.69	<.001	13.19
Prenatal violence	1.84	<.01	<0.01	.18	-0.82	.10	0.19	[-0.02; 0.73]	2.03	<.01	9.16

	Direct effect (X→Y)	<i>p</i>	Direct effect (X→M)	<i>p</i>	Direct effect (M→Y)	<i>p</i>	Indirect effect (X→M→Y)	95% CI [LB; UB]	Total effect	<i>p</i>	Proportion of total effect mediated [%]
INCREASE											
Oxytocin											
Adverse family situation	1.31	<.001	-0.08	.35	-0.78	.13	0.06	[-0.08; 0.30]	1.38	<.001	4.69
Trauma exposure	0.38	.01	-0.02	.54	-0.80	.08	0.02	[-0.05; 0.10]	0.39	<.001	4.47
Psychological stress											
Prenatal smoking	1.44	<.001	0.13	.77	0.04	.34	0.01	[-0.05; 0.07]	1.45	<.001	0.69
Prenatal violence	1.70	<.001	0.43	.47	0.03	.50	0.01	[-0.08; 0.13]	1.71	<.001	0.58
Adverse family situation	1.53	<.001	-0.07	.81	0.02	.69	0.00	[-0.04; 0.03]	1.53	<.001	0.07
Trauma exposure	0.56	<.001	0.11	.33	0.01	.87	0.00	[-0.02; 0.02]	0.56	<.001	0.18
RECOVERY											
Cortisol											
Prenatal smoking	1.33	<.01	-0.79	.08	-0.33	<.001	0.26	[0.02; 0.64]	1.59	<.001	16.32
Prenatal violence	1.69	<.01	-1.08	.09	-0.22	<.01	0.24	[-0.0004; 0.86]	1.93	<.01	12.41
Adverse family situation	1.40	<.001	-0.84	<.01	-0.28	<.01	0.23	[0.12; 0.49]	1.64	<.001	14.26
Trauma exposure	0.39	<.001	-0.24	<.05	-0.26	<.001	0.06	[0.01; 0.15]	0.45	<.001	13.40
Testosterone											
Prenatal smoking	1.43	<.001	0.09	.96	-0.02	.13	0.00	[-0.11; 0.09]	1.42	<.001	-0.14
Prenatal violence	1.81	<.01	-3.79	.15	-0.02	.23	0.06	[-0.02; 0.21]	1.88	<.01	3.42
Adverse family situation	1.54	<.001	-0.52	.68	-0.03	.08	0.01	[-0.05; 0.08]	1.55	<.001	0.85
Trauma exposure	0.39	<.001	-1.33	<.01	-0.02	.13	0.03	[-0.01; 0.07]	0.41	<.001	6.13
Oxytocin											
Prenatal smoking	1.53	<.01	-0.21	.11	-0.83	.07	0.18	[0.02; 0.74]	1.70	<.001	10.37
Prenatal violence	1.79	<.01	-0.28	.08	-0.93	.04	0.26	[0.03; 0.80]	2.05	<.01	12.83
Adverse family situation	1.28	<.001	-0.14	.09	-0.90	.06	0.13	[-0.01; 0.43]	1.41	<.001	8.99
Trauma exposure	0.33	.03	-0.06	.06	-1.03	.03	0.07	[-0.001; 0.20]	0.40	<.001	16.47
Psychological stress											
Prenatal smoking	1.43	<.001	0.45	.31	0.10	.04	0.04	[-0.04; 0.18]	1.47	<.001	2.72
Prenatal violence	1.64	<.001	1.15	.06	0.07	.11	0.08	[-0.02; 0.27]	1.72	<.001	4.65
Adverse family situation	1.51	<.001	0.60	.03	0.05	.34	0.03	[-0.03; 0.11]	1.54	<.001	1.95
Trauma exposure	0.55	<.001	0.20	.08	0.05	.22	0.01	[-0.01; 0.04]	0.56	<.001	1.79

Note. ^aThe standardized estimates of the effects are reported. Significant mediation effects are highlighted in bold. AUC_I=Area under the curve with respect to increase, M=psychoneuroendocrine mediator, UB=upper bound, X=risk factor, Y=CD status.

